Privileged Structures in the Design of Potential Drug Candidates for Neglected Diseases

被引:37
|
作者
Lima Leite, Ana Cristina [1 ]
Pontes Espindola, Jose Wanderlan [1 ]
de Oliveira Cardoso, Marcos Verissimo [2 ]
de Oliveira Filho, Gevanio Bezerra [1 ,3 ]
机构
[1] Univ Fed Pernambuco, Ctr Ciencias Saude, Dept Ciencias Farmaceut, BR-50740520 Recife, PE, Brazil
[2] Univ Pernambuco, Colegiado Nutr, Campus Petrolina, BR-56328903 Petrolina, PE, Brazil
[3] Fac Integracao Sertao, Rua Joao Luiz de Melo 2110, Serra Talhada, PE, Brazil
关键词
Privileged structures; phthalimide; isatine; indole; thiosemicarbazone; thiazole; thiazolidinone antiprotozoal chemotherapy; leishmania; plasmodium; trypanosoma; antiparasitic drugs; MYCOBACTERIUM-TUBERCULOSIS ACTIVITY; IN-VITRO ACTIVITY; TRYPANOSOMA-CRUZI; BIOLOGICAL EVALUATION; PHARMACOLOGICAL EVALUATION; ANTIMICROBIAL ACTIVITIES; PHTHALIMIDE DERIVATIVES; PLASMODIUM-FALCIPARUM; ANTIMALARIAL ACTIVITY; SELECTIVE INHIBITORS;
D O I
10.2174/0929867324666171023163752
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Privileged motifs are recurring in a wide range of biologically active compounds that reach different pharmaceutical targets and pathways and could represent a suitable start point to access potential candidates in the neglected diseases field. The current therapies to treat these diseases are based in drugs that lack of the desired effectiveness, affordable methods of synthesis and allow a way to emergence of resistant strains. Due the lack of financial return, only few pharmaceutical companies have been investing in research for new therapeutics for neglected diseases (ND). Methods: Based on the literature search from 2002 to 2016, we discuss how six privileged motifs, focusing phthalimide, isatin, indole, thiosemicarbazone, thiazole, and thiazolidinone are particularly recurrent in compounds active against some of neglected diseases. Results: It was observed that attention was paid particularly for Chagas disease, malaria, tuberculosis, schistosomiasis, leishmaniasis, dengue, African sleeping sickness (Human African Trypanosomiasis - HAT) and toxoplasmosis. It was possible to verify that, among the ND, antitrypanosomal and antiplasmodial activities were between the most searched. Besides, thiosemicarbazone moiety seems to be the most versatile and frequently explored scaffold. As well, phthalimide, isatin, thiazole, and thiazolidone nucleus have been also explored in the ND field. Conclusion: Some described compounds, appear to be promising drug candidates, while others could represent a valuable inspiration in the research for new lead compounds.
引用
收藏
页码:4323 / 4354
页数:32
相关论文
共 50 条
  • [21] Addressing the most neglected diseases through an open research model: The discovery of fenarimols as novel drug candidates for eumycetoma
    Lim, Wilson
    Melse, Youri
    Konings, Mickey
    Hung Phat Duong
    Eadie, Kimberly
    Laleu, Benoit
    Perry, Benjamin
    Todd, Matthew H.
    Ioset, Jean-Robert
    van de Sande, Wendy W. J.
    PLOS NEGLECTED TROPICAL DISEASES, 2018, 12 (04):
  • [22] Addressing the Most Neglected Diseases through an Open Research Model: the Discovery of Fenarimols as Novel Drug Candidates for Eumycetoma
    Lim, W.
    MEDICAL MYCOLOGY, 2018, 56 : S67 - S67
  • [23] Histone deacetylase enzymes as potential drug targets of Neglected Tropical Diseases caused by cestodes
    Vaca, Hugo R.
    Celentano, Ana M.
    Macchiaroli, Natalia
    Kamenetzky, Laura
    Camicia, Federico
    Rosenzvit, Mara C.
    INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE, 2019, 9 : 120 - 132
  • [24] The Chromenopyridine Scaffold: A Privileged Platform in Drug Design
    de Lima, Fabio Pedroso
    Costa, Marta
    Sousa, Ana
    Proenca, Maria Fernanda
    MOLECULES, 2024, 29 (13):
  • [25] Benzimidazole as a Privileged Scaffold in Drug Design and Discovery
    Kumar, Ram
    Babu, M. Arockia
    Pathak, Shilpi
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2024, 24 (17) : 1504 - 1528
  • [26] Privileged scaffolds for library design and drug discovery
    Welsch, Matthew E.
    Snyder, Scott A.
    Stockwell, Brent R.
    CURRENT OPINION IN CHEMICAL BIOLOGY, 2010, 14 (03) : 347 - 361
  • [27] Machine learning, artificial intelligence, and data science breaking into drug design and neglected diseases
    Pena-Guerrero, Jose
    Nguewa, Paul A.
    Garcia-Sosa, Alfonso T.
    WILEY INTERDISCIPLINARY REVIEWS-COMPUTATIONAL MOLECULAR SCIENCE, 2021, 11 (05)
  • [28] The Novartis institute for tropical diseases: drug discovery for neglected diseases
    Herrling, P.
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2006, 58 : A92 - A92
  • [29] Structure- and ligand-based drug design approaches for neglected tropical diseases
    Guido, Rafael V. C.
    Oliva, Glaucius
    Andricopulo, Adriano D.
    PURE AND APPLIED CHEMISTRY, 2012, 84 (09) : 1857 - 1866
  • [30] Drug discovery and development for neglected parasitic diseases
    Renslo, Adam R.
    McKerrow, James H.
    NATURE CHEMICAL BIOLOGY, 2006, 2 (12) : 701 - 710